Based on these results, a phase III, global, randomized clinical trial (NCT04447118) comparing the efficacy of pyrotinib to docetaxel as second line systemic therapy in patients with advanced, non-squamous NSCLC harboring HER2 exon 20 mutations) who have failed platinum-based chemotherapy was recently opened to enroll patients in September 2020. Here, ERBB2 is linked to non-small cell lung carcinoma.